Home | Business Development | Careers | Contact Us | Location Map | Sign In
Home >> Our Advantage > Alliances
E-mail this page Print this page

Panacea Biotec enjoys a rich tradition of collaborations and joint ventures with various industry players and business relationships with national & international research institutes, academic universities and commercial corporations for the purpose of securing in-licensing, out sourcing and other business opportunities and to develop strong product portfolio.

Panacea Biotec - Kremers Urban Inc. Alliance

Panacea Biotec, India's highly progressive research based health management company has entered into a strategic alliance with Kremers Urban Inc. (part of UCB Group) for 11 high barrier to entry generics, whose market size in US at the innovator level is around USD 4 billion.

The first product in this portfolio to reach the market is Tacrolimus Capsules that is being launched in US in Nov 2012. Panacea Biotec was granted approval of the product from the United States Food and Drug Administration (FDA) in September 2012. Tacrolimus is used along with other medications to prevent rejection (attack of a transplanted organ by the immune system of a person receiving the organ) in people who have received organ transplants. Tacrolimus is in a class of medications called immunosupressants. It works by decreasing the activity of the immune system to prevent it from attacking the transplanted organ. 

The total market size of Tacrolimus is approximately USD 892 million in US. Currently there are 5 generic players in US; namely Sandoz, Dr Reddy’s, Mylan, Watson and Accord Healthcare. The innovator brand Prograf® accounts for approximately 43% of Tacrolimus sales in terms of units sold and generics account for the remaining 57%. 

Under the terms of the agreement Panacea Biotec would be responsible for research, development, registration and commercial supplies of the products while Kremers Urban would be responsible for marketing, sales and distribution. The business collaboration is based on long term profit sharing by both companies.  

Submission of the first ANDA within this basket of 10 additional products was done in Sep 2012. The remaining 9 ANDAs would be submitted with USFDA over the next 16 months’ time period.


Panacea Biotec-Osmotica Alliance

“Panacea Biotec, has entered into a strategic alliance for the research, development and commercialization of drug delivery based, high barrier to entry generic and branded pharmaceutical products in US and key strategic markets across the globe, with Osmotica Pharmaceutical, a global pharmaceutical company specializing in drug delivery technologies. The collaboration is designed to build upon each company's highly complementary strengths and quality assets.

Under the collaboration, Panacea Biotec would lead product identification, research, development and manufacturing while Osmotica would lead product registration, legal matters, marketing, sales and distribution. The collaboration products are expected to be sold under an Osmotica and Panacea Biotec label. This collaboration is based on a 50:50 risk, investment and profit sharing by both companies and starts with a portfolio of 18 products across a broad range of therapeutic categories, with a provision to add new products by the Joint Steering Committee represented by both Osmotica and Panacea Biotec”

Panacea NewRise Hospital, Gurgaon

Panacea NewRise Hospital in which Panacea Biotec has majority interest is in final stage of construction and will be launched by the end of the year 2012. Panacea NewRise Hospital, a modern 225 bed Super Specialty Hospital is located in DLF City, Phase-3, Gurgaon ( Millennium City of India). The hospital is committed to provide “Excellence in Healthcare through customer service beyond conventions”

Nederlands Vaccine Institute (NVI), Netherlands.

The Company has entered into an agreement with NVI for manufacturing and marketing of Inactivated Polio Vaccine in global markets except Netherlands, Denmark, Norway and Finland.

National Research Development Corporation (NRDC), India.

The Company has an in-licensing arrangement with NRDC for manufacturing the Foot and Mouth Disease (FMD) vaccine developed by Indian Veterinary Research Institute (IVRI).

PT Bio Farma, Indonesia.

The Company has entered into an agreement with PT. Bio Farma, Indonesia to manufacture & market the Measles Vaccine and plans to supply the vaccine to UNICEF, PAHO and CIS, African, LATAM and Asian Countries in furtherance to Global Measles Reduction Strategy of WHO and UNICEF.

National Institute of Health, USA.

The Company has an in-licensing arrangement with National Institute of Health, USA, for use of a peptide based product for generation of hair follicles and hair growth. Pre-clinical toxicology studies will be shortly initiated.

National Institute of Immunology, India.

The Company has an exclusive ten-year license agreement with National Institute of Immunology, India for in-licensing of technology and processes for production of tissue culture derived formalin inactivated, Japanese encephalitis vaccine. The technology transfer and training of scientists has been completed and scale-up production for clinical trial purposes and optimization of various analytical and biological test methods, is under progress.

Biotech Consortium India Ltd.

The Company has a ten-year in-licensing arrangement with Biotech Consortium India Ltd. for the development, manufacture and marketing of anthrax vaccine developed by Jawahar Lal Nehru University, India. Phase I/IIa of human trials have been successfully completed and the Phase-IIb clinical trials are to begin shortly, subsequent to which the company plan to supply the anthrax vaccine to the U.S. government. For this purpose, the Company plans to initiate discussion with a U.S. based vaccine company for collaboration.